Log in
Enquire now
‌

US Patent 9181288 Azepane derivatives and methods of treating hepatitis B infections

Patent 9181288 was granted and assigned to Novira Therapeutics on November, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Novira Therapeutics
Novira Therapeutics
Current Assignee
Novira Therapeutics
Novira Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9181288
Date of Patent
November 10, 2015
Patent Application Number
14597814
Date Filed
January 15, 2015
Patent Citations Received
‌
US Patent 11766447 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
‌
US Patent 11788077 Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
Patent Primary Examiner
‌
Brian McDowell
Patent abstract

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. In an embodiment of the compounds provided herein, the compounds are of Formula Va:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9181288 Azepane derivatives and methods of treating hepatitis B infections

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.